Insights On Drug Development

31. Tailoring Formulations To Meet Precision‑Medicine Needs 1/26/2026

    Precision‑medicine formulation needs targeted design, adaptable workflows, and strong science. Thoughtful approaches improve performance, support patient needs, and help therapies advance successfully.

32. Flexible CDMO Solutions That Reduce Risk And Speed Time To Market 1/26/2026

    Agile, specialized CDMOs bring the technical depth and flexibility needed for complex drug programs, reducing risk and supporting aligned, efficient progress toward key clinical milestones.

33. Fast-Track Innovation, Address CMC Challenges In Expedited Pathways 1/26/2026

    Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

34. Understanding Surfactant Excipients In Biologic Formulations 1/26/2026

    Uncover surfactant characterization, polysorbate degradation, and advanced analytics, such as multidimensional LC, to strengthen stability assessment and formulation for biologics and advanced therapies.

35. Detecting Particles In Biologic And CGT Drug Products 1/26/2026

    Identify and characterize visible and subvisible particles that can form during biologic and cell or gene therapy development.

36. Developability Assessment And Early Formulation Studies 1/26/2026

    Early developability and pre‑formulation screening build strong biophysical data, reduce late‑stage risks, support candidate selection, and streamline biologics development toward clinical success.

37. AUC As An Alternative For Biologics, Gene Therapy Characterization 1/26/2026

    Learn how Analytical Ultracentrifugation enables detailed characterization of biologics, vaccines, and gene therapy vectors, offering a powerful alternative for R&D and emerging QC needs.

38. Integrated In Silico, Lab Assessments For Faster Drug Development 1/21/2026

    Integrated in‑silico and lab developability assessments flag molecular risks early, improving formulatability, manufacturability, and stability while reducing late‑stage failures, costs, and timelines.

39. A Roadmap For Navigating Biologic Development 1/21/2026

    A phase‑appropriate roadmap guides biologics from early formulation to commercialization through Quality by Design, strong analytics, stability optimization, and regulatory alignment.

40. A CRDO Path To Faster Biologic Development 1/21/2026

    A science‑driven CRDO model accelerates biologic development by combining expert formulation, analytics, and partnerships to reduce risk and improve outcomes.